Amid the Media Firestorm, Theranos Responds to FDA Issues
Earlier this week FDA posted two 483 documents on its website related to several problems it saw during inspections of Theranos’ facility. Following these now very-public issues related to design validation, complaint handling and shipment of “uncleared” product in interstate commerce, Theranos has issued a statement on its website.
- FDA issued two Form 483s. Theranos stated: “None of these observations were specific to Theranos’ analytical devices, software, or chemistries, or the manufacturing infrastructure for Theranos’ analytical devices or chemistries. All observations from this inspection pertained to quality systems associated with the use of one of our Nanotainer™ tubes under the CLIA lab quality framework instead of the FDA quality framework.”
- FDA observed that Theranos’ Nanotainer tubes were uncleared and being shipped in interstate commerce. Theranos stated: “In our discussions with FDA, we determined that it was appropriate to temporarily pause use of the Nanotainer tubes that had been operating under the CLIA lab quality systems and are currently waiting for clearance… We are in close contact with FDA in this process and are confident that we will achieve clearance of the Nanotainer tubes.”
And finally, a Form 483 is not a warning letter, stressed Theranos. “These observations are, by their very nature, not final agency determinations. Contrary to what we’ve seen published, no warning letter was or has been discussed or mentioned.”
Review the full statement by Theranos.
Related Articles
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
Balwani was found guilty on 10 counts of wire fraud and two counts of conspiracy to commit wire fraud for misleading investors about the financial health of the healthcare startup. He faced up to 20 years in prison for each…
-
Holmes, who was found guilty in January on three counts of investor fraud and one count of conspiracy to commit fraud related to her blood-testing startup, faced up to 20 years in prison for each guilty count.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
